EvidentIQ Germany, formerly known as XClinical, a top provider of EDC software, is proud to mark a decade of fruitful collaboration with Cardialysis, a renowned CRO & Core Laboratory based in the Netherlands. For the past ten years, EvidentIQ Germany and Cardialysis have joined forces to achieve impressive accomplishments in clinical research. Together, they have […]
continue reading
Today, EvidentIQ, a leading provider of end-to-end eClinical and Patient Insights solutions, announced the acquisition of Asthenis GmbH, the market leader in cancer documentation software in the DACH region (Germany, Austria and Switzerland). EvidentIQ, based in Hamburg, is a leading clinical data science group, offering an end-to-end platform of state-of-the art eClinical solutions (eConsent, EDC, […]
continue reading
Today, EvidentIQ, a leading provider of end-to-end eClinical and Patient Insights solutions, proudly announces a strategic leadership restructuring, setting the stage for the company’s continued growth and commitment to delivering unparalleled results for its clients. After three highly successful years of guiding EvidentIQ’s evolution and establishing it as a formidable player in the healthcare industry, […]
continue reading
EvidentIQ, the innovative provider of advanced clinical trial management solutions has joined forces with Quinta Analytica, a renowned GCP/GLP/GMP-certified European CRO and part of the Conscio Group. This collaboration aims to enhance the efficiency and effectiveness of data collection processes for Phase 1 studies, utilizing EvidentIQ’s Clindex eClinical system. According to Dr. Renata Vyhnálková, Quality […]
continue reading
Michael Chekroun, founder of Carenity and outgoing President, will be stepping down from his role as of today. Lise Radoszycki, former COO, will be taking the helm as the new President, bringing extensive experience and expertise that will propel the company into its next phase of expansion and development. Michael Chekroun has played for the […]
continue reading
EvidentIQ launches a new Managed Service Model that not only supports the use of the open-source solution OpenStudyBuilder, but also helps clients customizing it to their specific requirements. Last year EvidentIQ released alongside Novo Nordisk, Neo4j, and Microsoft, a new solution for managing clinical data standards and study design specifications, the OpenStudyBuilder. In the world […]
continue reading
EvidentIQ launches a new tool designed specifically to bridge the gap between a simple reporting and a PV system. EvidentIQ aspired to create a tool that could solve the problem of having a reliable safety notification tool to monitor adverse drug reactions (ADRs) outside of the scope of a full PV system in a trial […]
continue reading
Today, EvidentIQ, a leading clinical data science group and Keyrus Life Science, the Connected Contract Research Organization (C²RO), announced the signing of their partnership. The synergy between both companies will improve automation, efficiency and agility in clinical research by leveraging new eClinical capabilities. EvidentIQ, based in Hamburg, is a leading clinical data science group, offering […]
continue reading
Today, EvidentIQ, a leading provider of end-to-end eClinical and Patient Insights solutions, announced the acquisition of DACIMA Software, a Canadian clinical software company founded in 2006. EvidentIQ, based in Hamburg, is a leading clinical data science group, offering an end-to-end platform of state-of-the art eClinical solutions (eConsent, EDC, CTMS, eCOA,) that helps its customers with […]
continue reading